MATCH SIZE AND QUANTITY
Build your comparison.
Choose a labeled amount and selection to load matching prices.
Vial comparison
Compare research vials explicitly labeled CJC-1295 without DAC. The no-DAC wording is part of the product match, not an optional detail to drop when comparing prices.
MATCH SIZE AND QUANTITY
Choose a labeled amount and selection to load matching prices.
GO BEYOND THE PRICE
Select a strength and selection above to view price history, save a price watch or add it to your basket.
DOCUMENTATION PASSPORTS
Inspect the source report, recorded lot and document access. A report link does not confirm the batch currently shipping.
Loading documentation records…
Reported quantities in this family: 1, 3, 6, 10. Counts and units must be matched to the exact listing.
This group recognizes labels including CJC-1295 without DAC, CJC-1295 W/O DAC, Mod GRF 1-29 and Modified GRF 1-29. Check the original listing for that identity before matching an offer. A title that says only CJC-1295 does not establish that it belongs in the no-DAC group.
Compare the same labeled amount and pack count; the catalog includes 2 mg, 5 mg and 10 mg no-DAC vials, among other sizes. Keep CJC-1295 with DAC and CJC-1295/Ipamorelin blends separate. A blend's combined milligrams do not establish how much of either component it contains.
Compare within each strength. Every row covers one vial and includes only listings marked in stock with known quantities.
| Strength | Selection | Lowest listed total price | Price per mg | Supplier count | Compare |
|---|---|---|---|---|---|
| 2 mg | 1 vial | $13.74 | $6.87 | 2 | Compare |
| 5 mg | 1 vial | $18.69 | $3.74 | 17 | Compare |
| 10 mg | 1 vial | $27.49 | $2.75 | 11 | Compare |
| 11 mg | 1 vial | $29.14 | $2.65 | 1 | Compare |

122 products · 249 listings

153 products · 275 listings

20 products · 27 listings

44 products · 56 listings
26 products · 27 listings

15 products · 20 listings

35 products · 36 listings

32 products · 41 listings

4 products · 4 listings

20 products · 34 listings

36 products · 58 listings

42 products · 96 listings

29 products · 39 listings

24 products · 29 listings

20 products · 30 listings

23 products · 26 listings

40 products · 50 listings

26 products · 42 listings
28 products · 30 listings

19 products · 24 listings
18 products · 20 listings
34 products · 47 listings

41 products · 52 listings

32 products · 43 listings

35 products · 45 listings

50 products · 65 listings

18 products · 66 listings

37 products · 58 listings

38 products · 72 listings
9 listings from direct supplier captures and 34 listings from aggregator reports. Capture and import dates record when data was obtained; they do not guarantee the supplier’s current price or stock.
Listings include out-of-stock and unconfirmed-stock records. Inclusion does not certify a supplier, a batch or a product. Read how matching and source dates work.
They are distinct labels in the catalog, and the comparison does not treat them as equivalent products. The exact DAC designation must match before prices can be compared within this group.
Mod GRF 1-29 and Modified GRF 1-29 are recognized supplier-label aliases in this index. Read the original product description and documentation to confirm the identity of the specific offer.
The shared total does not establish an equivalent selection. A blend includes multiple components; inspect the stated amount of each. This page compares single-compound no-DAC vials separately from those recipes.
FROM PEPTIDES CALCULATOR
Source profile reviewed 2026-10-01 · Imported 2026-10-22. Read the full compound profile
ModGRF 1-29 is the 29-residue growth hormone-releasing hormone fragment GRF(1-29) with four amino acid substitutions that ConjuChem introduced in the early 2000s to resist breakdown by DPP-4 and oxidation; it is the peptide half of CJC-1295, which adds a maleimidopropionyl group on an extra lysine so the drug binds albumin and lasts about a week, hence the community names CJC-1295 without DAC or No DAC. The modified fragment itself was characterized in rat pituitary cells and rats during CJC-1295 development, and every human trial used the albumin-binding DAC version, so there is no published human dosing, pharmacokinetic or safety study of the no-DAC peptide. It is sold as a research chemical and used almost always alongside a ghrelin-receptor peptide such as ipamorelin; WADA prohibits GHRH analogues including CJC-1295 at all times, and the FDA listed CJC-1295 among compounding substances that may present significant safety risks from September 2023 until the nomination was withdrawn in April 2026.
Preclinical work characterized modified GRF analogues and the later albumin-bound DAC construct.
The frequently cited 2006 trial tested long-acting CJC-1295 with DAC, not the no-DAC form (ModGRF 1-29).
Direct controlled human pharmacokinetic and outcomes data for the no-DAC product are sparse.
Background is reproduced from Peptides Calculator with attribution. The source describes compound-level research. It does not evaluate the identity, quality or suitability of a listed supplier’s product or batch.